CORT (Corcept Therapeutics) Short Percentage of Float


CORT Corcept Therapeutics Inc CORT
82 GF Score
Price $81.56
GF Value $61.59
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Corcept Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CORT vs PCVX, IBRX, HALO: Short Percentage of Float Comparison

For the Biotechnology subindustry, Corcept Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corcept Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Short Percentage of Float falls into.


CORT
82GF Score
Corcept Therapeutics Inc CORT
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corcept Therapeutics (CORT) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of $81.56 is trading 32.4% above its estimated GF Value™ of $61.59. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for CORT:

  • Short Percentage of Float:
  • GF Value™: $61.59 vs. price of $81.56 (32.4% above fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score

Get the complete analysis for CORT

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.56
Price
$61.59
GF Value